ZBIO earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -3.46. Updated 2026-07-23.
Zenas BioPharma (ZBIO) Research Hub
Zenas BioPharma (ZBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 31.12 USD (-3.62%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.46, market cap 1.42B. This hub links to the full technical, earnings and options research available for ZBIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 31.12 USD (-3.62%) |
| 52-week range | 18.06 USD – 33.99 USD |
| Trend regime | Range |
| 14-day RSI | 45.4 (Neutral) |
| Trailing P/E | -3.46 |
| Market cap | 1.42B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ZBIO
Covered Call on ZBIO: how it works, illustrative setup around the real 31.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ZBIO: how it works, illustrative setup around the real 31.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ZBIO: how it works, illustrative setup around the real 31.12 USD price, max profit/loss, breakeven and when to use it. Educational.
ZBIO technical analysis: range, last 31.12 USD, RSI 45.4, 52w range 18.06 USD–33.99 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ZBIO in?
Zenas BioPharma (ZBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ZBIO in an uptrend or downtrend?
As of 2026-09-11, ZBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ZBIO's trailing P/E ratio?
ZBIO's trailing P/E is -3.46, with a market cap of 1.42B. See the earnings research page for full valuation detail.
When does ZBIO next report earnings?
ZBIO is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.89 USD.